Adicet Bio, Inc. (ACET)
About Adicet Bio, Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$116.8M
- Total assets
- $192.4M
- Market cap
- $67.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $122.1M
- Operating income
- -$122.1M
- Income tax
- $0
- Net income
- -$116.8M
- EPS (basic)
- $-16.95
- EPS (diluted)
- $-16.95
Balance sheet
- Total assets
- $192.4M
- Current assets
- $160.9M
- Total liabilities
- $33.1M
- Current liabilities
- $21.5M
- Shareholders’ equity
- $159.2M
Cash flow
- Operating cash flow
- -$95.2M
- Investing cash flow
- $2.4M
- Financing cash flow
- $75.2M
- Net cash flow
- -$17.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $67.9M
- EPS (diluted)
- $-16.95
- Shares outstanding
- 8.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 16, 2020
Adicet Bio, Inc. (ACET) Stock Price
- Reported a net loss of $116.8M.
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Adicet Bio, Inc..
Write a review
News about Adicet Bio, Inc.
News & sentiment via Polygon.io
Adicet Bio, Inc.: frequently asked questions
Is Adicet Bio, Inc. an American company?
Adicet Bio, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Adicet Bio, Inc. headquartered?
Adicet Bio, Inc. is headquartered in Boston, Massachusetts, United States.
Is Adicet Bio, Inc. publicly traded?
Yes — Adicet Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol ACET on the NASDAQ.
What does Adicet Bio, Inc. do?
Adicet Bio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
